- Project 1 Cancer is a complex, dynamical system wherein transitions across scales are non-linear. Each transition, such as the decision to express a certain gene product, is governed by a cells' content and history in response to local microenvironmental signals. Hence, cancer is an open system, as the cancer is in communication with the local environment, which can be manipulated. These microenvironments select for specific cellular phenotypes and hence, resident clades of cells are often heterogeneously distributed within sub-regions (?habitats?) of individual tumors; which can be defined by in-vivo and ex-vivo imaging. In the first PSOC period, we investigated the impact of microenvironmental factors (pH, hypoxia) on carcinogenesis itself. Herein, we change our trajectory, in concert with the entire PSOC, to investigate therapeutically actionable consequences of microenvironmental heterogeneity. Specifically, we will investigate:
Aim 1, tumor oxygenation, which can be targeted with specific hypoxia-activated pro-drugs;
Aim 2, metabolic heterogeneity and tumor acidity, which can be targeted by specific metabolic inhibitors and buffer therapies. Specifically we will follow promising preliminary data to investigate their impact on immune therapies; and, in response to a new trial in Project 2, Aim 3 will examine the effect of hormone-deprivation therapies on tumor-stromal interactions. Because these dynamics are complex and non-linear, we will deploy application-specific mathematical models that are developed through integration with the Bench-to-Beside Core. These models and the experiments that inform them will be iteratively improved over the course of this grant with the goal of developing novel approaches based on Evolutionary Dynamics, which can be handed off to Project 2, and integrated into novel clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA193489-05
Application #
9774760
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Subramanian, Hemachander; Gatenby, Robert A (2018) Evolutionary advantage of directional symmetry breaking in self-replicating polymers. J Theor Biol 446:128-136
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
Karolak, Aleksandra; Rejniak, Katarzyna A (2018) Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue. Bull Math Biol :
Shah, Seema; Brock, Ethan J; Ji, Kyungmin et al. (2018) Ras and Rap1: A tale of two GTPases. Semin Cancer Biol :
Gallaher, Jill A; Enriquez-Navas, Pedro M; Luddy, Kimberly A et al. (2018) Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies. Cancer Res 78:2127-2139
Maley, Carlo C; Aktipis, Athena; Graham, Trevor A et al. (2017) Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer 17:605-619
Ibrahim-Hashim, Arig; Robertson-Tessi, Mark; Enriquez-Navas, Pedro M et al. (2017) Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution. Cancer Res 77:2242-2254
Brown, Joel S; Cunningham, Jessica J; Gatenby, Robert A (2017) Aggregation Effects and Population-Based Dynamics as a Source of Therapy Resistance in Cancer. IEEE Trans Biomed Eng 64:512-518
Gatenby, Robert A; Brown, Joel (2017) Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer. Biochim Biophys Acta Rev Cancer 1867:162-166
Silva, Ariosto; Silva, Maria C; Sudalagunta, Praneeth et al. (2017) An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma. Cancer Res 77:3336-3351

Showing the most recent 10 out of 22 publications